NEW YORK (AP) — The U.S. stock market ticked higher on Wednesday, led by its most influential stock, Nvidia. The S&P 500 rose 0.6% and pulled a bit closer to its all-time high set late last month. The ...

Integration and automation leader achieves 50% customer growth in just over three years Company now serves 30,000+ customers worldwide, including more than a quarter of the Fortune 500 Boomi powers ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the pharmaceutical company said Wednesday, ...

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports ...

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further study in older adults.

The Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with mRNA technology, the company said.

Moderna CEO Stephane Bancel says the company does not plan to invest in late-stage vaccine trials because of growing scrutiny of immunizations from US officials. He speaks with Lisa Abramowicz at the ...

Moderna (MRNA) CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S. government pushes back against immunizations. “We have said ...

Moderna has submitted a revised approach to streamline approval based on age-specific indications. ・The company proposed a ...

Q4 2025 earnings call highlights: revenue, cost cuts, cash outlook, FDA flu setback, and 2026 growth guidance—read key insights now.

Jan 22 (Reuters) - Moderna does ‌not plan to ‌invest in new late-stage vaccine trials because of growing opposition to ‍immunizations from U.S. officials, CEO Stephane Bancel said ⁠in an interview ...

Moderna and Merck & Co Inc (NYSE:MRK) released five‑year median follow‑up data from the Phase 2b KEYNOTE‑942/mRNA‑4157‑P201 trial, which is testing ...